TERC and myeloid sarcoma: We found that TERC rs35073794 is associated with about 2.4-fold decreased odds of MS development under the codominant, dominant, overdominant, and additive models (OR: 0.408, (95% CI: 0.275–0.603), p < 0.001; OR: 0.412 (95% CI: 0.279–0.610), p < 0.001; OR: 0.404 (95% CI: 0.273–0.598), p < 0.001; OR: 0.427 (95% CI: 0.289–0.629), p < 0.001, respectively).